Pfizer Director Cyrus Taraporevala Acquires Phantom Stock Units via Deferred Compensation

Transaction Overview

On September 25, 2026, Pfizer Inc ($PFE) Board Director Cyrus Taraporevala acquired 1,307.987 phantom stock units at a stated price of $28.67 per unit, representing a total value of approximately $37,500.00. The filing was reported on Form 4 on September 29, 2026.

Nature of Transaction & Compensation Context

As indicated in the footnotes:

• Each phantom stock unit represents the economic equivalent of one share of Pfizer common stock.
• The units represent deferred director compensation (and/or dividend equivalents thereon).
• Settlement occurs in either cash or common stock at the director's election following retirement from the Board of Directors.

Ownership Post-Transaction

Following this routine quarterly credit, Taraporevala directly holds 38,805.658 phantom stock units.

Market & Trading Significance

This transaction carries Low trading significance. It reflects an automated or scheduled deferral of board compensation into phantom stock rather than a discretionary open-market equity purchase or sale, providing minimal insight into near-term sentiment on Pfizer's stock.